View the accessible transcript of this podcast
Professor Pamela Kearns talks to Professor Allan Gaw about CATAYLST, a phase 2 platform trial which was designed to rapidly identify potential COVID19 treatments during the pandemic.
Professor Kearns explains how the adaptive design of the trial and the Bayesian statistical approach were crucial to quickly acquire go/no go decisions on which drugs should be trialled in larger COVID19 trials like RECOVERY. She also recognises how the collaborative research culture in the UK, combined with the coordinated efforts of the UK research ecosystem, made the UK "a fantastic place to be able to find the best treatments for COVID-19."
This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517
To find out more about how the NIHR supports complex and innovative design trials visit: www.nihr.ac.uk/innovative-trials
